{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["De Vries C"],"funding":["NIDCR NIH HHS","European Research Council"],"pagination":["e005111"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11792289"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["<h4>Objective</h4>The antibody response against <i>Porphyromonas gingivalis</i> (<i>Pg</i>) is elevated in rheumatoid arthritis (RA), especially in patients with anti-citrullinated protein antibodies (ACPA). Here, we investigated whether antibodies against the <i>Pg</i> virulence factor arginine gingipain (Rgp) are associated with the RA-risk phase and development of arthritis.<h4>Methods</h4>At-risk individuals were included in a prospective study (Risk-RA) based on a positive anti-cyclic citrullinated peptide 2 (CCP2) antibody test, and having musculoskeletal complaints but no signs of arthritis. Study participants were followed for ≥3 years (arthritis-free, n=165) or until arthritis onset (progressors, n=95). Anti-Rgp IgG was measured in Risk-RA (260 baseline and 247 follow-up samples) "],"journal":["RMD open"],"pubmed_title":["&lt;i&gt;Porphyromonas gingivalis&lt;/i&gt; associates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population."],"pmcid":["PMC11792289"],"funding_grant_id":["772209","R01 DE022597"],"pubmed_authors":["De Vries C","Circiumaru A","Kisten Y","Hensvold A","Potempa B","Lundberg K","Mathsson-Alm L","Westerlind H","Potempa J","Dehara M"],"additional_accession":[]},"is_claimable":false,"name":"&lt;i&gt;Porphyromonas gingivalis&lt;/i&gt; associates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population.","description":"<h4>Objective</h4>The antibody response against <i>Porphyromonas gingivalis</i> (<i>Pg</i>) is elevated in rheumatoid arthritis (RA), especially in patients with anti-citrullinated protein antibodies (ACPA). Here, we investigated whether antibodies against the <i>Pg</i> virulence factor arginine gingipain (Rgp) are associated with the RA-risk phase and development of arthritis.<h4>Methods</h4>At-risk individuals were included in a prospective study (Risk-RA) based on a positive anti-cyclic citrullinated peptide 2 (CCP2) antibody test, and having musculoskeletal complaints but no signs of arthritis. Study participants were followed for ≥3 years (arthritis-free, n=165) or until arthritis onset (progressors, n=95). Anti-Rgp IgG was measured in Risk-RA (260 baseline and 247 follow-up samples) ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-04T07:26:22.241Z","creation":"2025-04-04T07:26:22.241Z"},"accession":"S-EPMC11792289","cross_references":{"pubmed":["39890206"],"doi":["10.1136/rmdopen-2024-005111"]}}